<?xml version="1.0"?>

<document>
	<title>Tobramycin ototoxicity.  Repeated courses of high dosage treatment
   in children with cystic fibrosis.</title>

	<author>Thomsen-J.</author>
	<author>Friis-B.</author>
	<author>Jensen-K.</author>
	<author>Bak-Pedersen-K.</author>
	<author>Larsen-P-K.</author>

	<source>J-Antimicrob-Chemother. 1979 May. 5(3). P 257-60.</source>

	<abstract>Fifty-three patients with cystic fibrosis were treated with large
   doses of tobramycin sulphate, 10 mg/kg/24 h.  Patients received an
   average of 3.2 courses, each lasting 10 to 14 days.  The patients
   were examined with audiometric and vestibular tests, and in one
   patient, a 10-year-old girl, we found a transient high tone loss at
   8000 Hz bilaterally that might be attributed to the tobramycin
   treatment.  All patients had normal kidney function.  High dose
   tobramycin treatment in children with normal kidney function gives
   minimal clinical risks of adverse ototoxic effects, even after
   repeated courses of treatment.</abstract>

	<majorsubject>ANTIBIOTICS: ae</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: co</majorsubject>
	<majorsubject>EAR-DISEASES: ci</majorsubject>
	<majorsubject>PSEUDOMONAS-INFECTIONS: dt</majorsubject>
	<majorsubject>RESPIRATORY-TRACT-INFECTIONS: dt</majorsubject>
	<majorsubject>TOBRAMYCIN: ae</majorsubject>

	<minorsubject>CHILD</minorsubject>
	<minorsubject>DRUG-ADMINISTRATION-SCHEDULE</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>HEARING-DISORDERS: ci</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>MALE</minorsubject>
	<minorsubject>PSEUDOMONAS-INFECTIONS: co</minorsubject>
	<minorsubject>RESPIRATORY-TRACT-INFECTIONS: co</minorsubject>
	<minorsubject>TOBRAMYCIN: ad, tu</minorsubject>

	<reference>001   BODEY GP              ANTIMICROB AGENTS CHEMOTHER      2   109 972</reference>
	<reference>002   BREZEZINSKA M         BIOCHEMISTRY NY                  2   671 972</reference>
	<reference>003   BRUMMET RE            ARCH OTOLARYNGOL                94    59 971</reference>
	<reference>004   BRUMMET RE            ARCH OTOLARYNGOL                96   505 972</reference>
	<reference>005   BRUMMET RE            ARCH OTOLARYNGOL               101   540 975</reference>
	<reference>006   DRASAR FA             BR MED J                         2  1284 976</reference>
	<reference>007   FEDERSPIL P           PROC TOBRAMYCIN SEL 8TH INT C         38 973</reference>
	<reference>009   HIGGINS CE            ANTIMICROB AGENTS CHEMOTHER      7   332 967</reference>
	<reference>010   HOFF GE               SCAND J INFECT DIS               6   333 974</reference>
	<reference>011   LOGAN TB              ARCH OTOLARYNGOL                99   190 974</reference>
	<reference>012   MCCRAE WM             SCOTT MED J                     21    68 976</reference>
	<reference>013   NEU HC                J INFECT DIS SUPPL             134   206 976</reference>
	<reference>014   PRAZMA J              LARYNGOSCOPE                    86   259 976</reference>
	<reference>015   STUPP HF              ACTA OTOLARYNGOL STOCKH SUPPL  262     1 970</reference>
	<reference>016   WILSON P              BR MED J                         1   259 977</reference>

	<citation>1   RIFF L                SEM PERINATOL                    6   155 982</citation>
	<citation>2   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982</citation>
	<citation>3   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982</citation>
	<citation>4   BEREZHINSKAYA VV      ANTIBIOTIKI                     28   218 983</citation>
	<citation>5   RYBAK LP              AM J OTOL                        6   482 985</citation>
	<citation>6   FRASER GL             DRUG INTEL CLIN PHARM           19   757 985</citation>
	<citation>7   HUY PTB               J CLIN INVEST                   77  1492 986</citation>
	<citation>8   PEDERSEN SS           ANTIMICROB AGENTS CHEMOTHER     31   594 987</citation>

</document>
